Portal de investigación
Papel de la heterogeneidad tumoral y la reprogramación dinámica de la célula tumoral en la resistencia a anticuerpos anti-HER2 en cáncer de mama HER2 positivo
Datos básicos
- Protocolo:
- PI15/01617
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- 2016
- Año de finalización:
- 2018
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Pineda, B; (...); Eroles, P
Article. 10.1186/s13148-019-0626-0. 2019
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
Lluch, A; (...); Albanell, J
Article. 10.1016/j.ejca.2019.07.003. 2019
High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer.
Muntasell, Aura; (...); Lopez-Botet, Miguel
Article. 10.1158/2326-6066.CIR-18-0896. 2019
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Tormo, E; (...); Eroles, P
Article. 10.1038/s41598-019-41472-y. 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Fernandez-Nogueira, P; (...); Bragado, P
Article. 10.1158/1078-0432.CCR-19-0353. 2020
